UK's MHRA approves Lecanemab, a potential Alzheimer's drug, for private prescription use; NICE to decide on NHS rollout.

Alzheimer's drug Lecanemab, which may slow cognitive decline by 27%, is set to be approved for private prescription use in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA). The National Institute for Health and Care Excellence (NICE) will determine if the drug is suitable for NHS rollout. Lecanemab, a monoclonal antibody medication, has already been approved for use in the US and aims to clear toxic amyloid proteins from the brain. However, the European Medicine Agency rejected the drug due to concerns about side effects like swelling and potential brain bleeds.

August 21, 2024
176 Articles